irinotecan has been researched along with atropine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hagiwara, T; Hirohashi, M; Kakihata, K; Kasai, Y; Kitano, Y; Kobayashi, R; Mori, K; Nagai, E; Nomura, M; Takasuna, K | 1 |
| Henja, MH; Kornek, GV; Raderer, M; Scheithauer, W; Valencak, J | 1 |
| Adjei, AA; Alberts, SA; Burch, PA; Elfring, G; Erlichman, C; Goldberg, RM; Miller, LL; Pitot, HC; Reid, JM; Rubin, J; Schaaf, LJ; Skaff, PA; Sloan, JA | 1 |
| Blandizzi, C; Colucci, R; Danesi, R; De Paolis, B; Del Tacca, M; Di Paolo, A | 1 |
| Aliustaoglu, M; Aydin, SZ; Dane, F; Ekenel, M; Gumus, M; Karamanoglu, A; Sengoz, M; Turhal, SN; Yumuk, PF | 1 |
| Ambreen, S; Denha, EJ; Lohia, P; Mir, TA; Rahim, A; Shaikhli, RA; Yassin, AS | 1 |
1 review(s) available for irinotecan and atropine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for irinotecan and atropine
| Article | Year |
|---|---|
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Topics: Adjuvants, Anesthesia; Adult; Aged; Aged, 80 and over; Antidiarrheals; Antiemetics; Antineoplastic Agents, Phytogenic; Area Under Curve; Atropine; Camptothecin; Colorectal Neoplasms; Dexamethasone; Digestive System; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Follow-Up Studies; Gallbladder Neoplasms; Glucuronates; Humans; Irinotecan; Loperamide; Male; Maximum Tolerated Dose; Middle Aged; Time Factors | 2000 |
The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Atropine; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Irinotecan; Male; Middle Aged; Muscarinic Antagonists; Neoplasm Metastasis | 2004 |
9 other study(ies) available for irinotecan and atropine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Atropine; Camptothecin; Cecum; Diarrhea; Drugs, Chinese Herbal; Enzyme Inhibitors; Flavonoids; Glucuronidase; Intestines; Irinotecan; Male; Rats; Rats, Wistar | 1995 |
Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Topics: Abdominal Pain; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atropine; Blood Pressure; Camptothecin; Cholinergic Fibers; Colorectal Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Parasympatholytics; Salivation; Topoisomerase I Inhibitors | 1998 |
Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study.
Topics: Acetylcholinesterase; Animals; Antineoplastic Agents, Phytogenic; Atropine; Blood Pressure; Camptothecin; Cardiovascular System; Cholinesterase Inhibitors; Erythrocytes; Heart Atria; Heart Rate; Irinotecan; Male; Physostigmine; Rats; Rats, Wistar; Statistics, Nonparametric; Vagus Nerve | 2001 |
Irinotecan inducing sinus pause bradycardia in a patient with small round cell cancer.
Topics: Adult; Anti-Arrhythmia Agents; Atropine; Bradycardia; Echocardiography; Female; Humans; Irinotecan; Topoisomerase I Inhibitors | 2020 |